KR102245027B1 - Composition for improving sleep disorder containing lettuce and Scutellariae extract as an active ingredient - Google Patents
Composition for improving sleep disorder containing lettuce and Scutellariae extract as an active ingredient Download PDFInfo
- Publication number
- KR102245027B1 KR102245027B1 KR1020170155122A KR20170155122A KR102245027B1 KR 102245027 B1 KR102245027 B1 KR 102245027B1 KR 1020170155122 A KR1020170155122 A KR 1020170155122A KR 20170155122 A KR20170155122 A KR 20170155122A KR 102245027 B1 KR102245027 B1 KR 102245027B1
- Authority
- KR
- South Korea
- Prior art keywords
- lettuce
- golden
- extract
- extract powder
- sleep
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 120
- 235000003228 Lactuca sativa Nutrition 0.000 title claims abstract description 81
- 241000208822 Lactuca Species 0.000 title claims abstract description 73
- 208000019116 sleep disease Diseases 0.000 title claims abstract description 56
- 239000004480 active ingredient Substances 0.000 title claims abstract description 18
- 208000020685 sleep-wake disease Diseases 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 title abstract description 26
- 239000008187 granular material Substances 0.000 claims abstract description 48
- 230000007958 sleep Effects 0.000 claims abstract description 28
- 235000013402 health food Nutrition 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 240000008415 Lactuca sativa Species 0.000 claims abstract description 8
- 206010000117 Abnormal behaviour Diseases 0.000 claims abstract description 5
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims abstract description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 5
- 206010020765 hypersomnia Diseases 0.000 claims abstract description 5
- 206010022437 insomnia Diseases 0.000 claims abstract description 5
- 201000003631 narcolepsy Diseases 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 86
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000002131 composite material Substances 0.000 claims description 26
- 238000002156 mixing Methods 0.000 claims description 19
- 229930091371 Fructose Natural products 0.000 claims description 13
- 239000005715 Fructose Substances 0.000 claims description 13
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 150000001720 carbohydrates Chemical class 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 230000003860 sleep quality Effects 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- 150000008163 sugars Chemical class 0.000 claims description 8
- 230000027288 circadian rhythm Effects 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 6
- 239000010931 gold Substances 0.000 claims description 6
- 229910052737 gold Inorganic materials 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- 238000005243 fluidization Methods 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 11
- 235000019658 bitter taste Nutrition 0.000 abstract description 6
- 241000207929 Scutellaria Species 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 description 12
- 238000000605 extraction Methods 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 238000002834 transmittance Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- -1 helazepam Chemical compound 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 208000022925 sleep disturbance Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010041347 Somnambulism Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000001573 Cataplexy Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005439 Sleep paralysis Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 230000008665 sleep physiology Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
본 발명은 상추 및 황금 추출물을 유효성분으로 함유하는 수면 장애 개선용 조성물에 관한 것으로, 보다 구체적으로 상추(Lactuca sativa) 및 황금(Scutellaria baicalensis) 복합 추출물을 분말 과립으로 제조 시 용해도가 우수하고, 용해하여 음용 시 쓴맛이 거의 없고 추출물 특유의 향을 마스킹하며 우수한 수면 증진 효과를 나타내므로, 불면증, 기면증, 수면 중 이상행동, 과수면증 등을 포함하는 수면 장애 예방 또는 치료용 약학적 조성물, 또는 수면 장애 예방 또는 개선용 건강식품으로 유용하게 사용될 수 있다. The present invention relates to a composition for improving sleep disorders containing lettuce and golden extract as an active ingredient, more specifically lettuce ( Lactuca sativa ) and golden ( Scutellaria) baicalensis ) When the complex extract is made into powdered granules, it has excellent solubility, has little bitter taste when dissolved and consumed, masks the unique scent of the extract, and exhibits excellent sleep enhancement effects, so insomnia, narcolepsy, abnormal behavior during sleep, and hypersomnia It may be usefully used as a pharmaceutical composition for preventing or treating sleep disorders, including the like, or as a health food for preventing or improving sleep disorders.
Description
본 발명은 상추 및 황금 추출물을 유효성분으로 함유하는 수면 장애 개선용 조성물에 관한 것으로, 보다 구체적으로 상추 및 황금 추출물을 유효성분으로 함유하는 수면 질환 또는 수면 장애 예방 또는 치료용 약학적 조성물, 또는 수면 질 개선, 일주기 리듬 변화를 위한 조성물, 또는 건강식품에 관한 것이다.
The present invention relates to a composition for improving sleep disorders containing lettuce and golden extract as an active ingredient, and more specifically, a pharmaceutical composition for preventing or treating sleep disorders or sleep disorders containing lettuce and golden extract as active ingredients, or It relates to a composition for quality improvement, circadian rhythm change, or health food.
잠을 자면서 보내는 시간이 우리 일생의 1/3을 차지할 정도로 수면은 우리 모두에게 중요하다. 수면이란 눈이 감긴 채 의식 활동이 쉬는 상태를 말하며 사람이 낮 동안 활동하면서 사용한 에너지를 보충하고 신체활동으로 인해 쌓인 피로를 회복하는 중요한 과정이다. 수면은 에너지와 피로 회복을 하는 시간일 뿐만 아니라 인간의 성장에 꼭 필요한 성장호르몬이 가장 많이 분비되는 시간이다. 우리 몸에서 뇌는 생명 유지를 위한 모든 생리적 기능을 총괄하는 곳으로 이 뇌가 적절한 활동의 균형을 유지하기 위해 반드시 휴식이 필요하며, 이러한 휴식은 대부분 수면 시간에 이루어진다.Sleep is so important to all of us that the time we spend sleeping takes up a third of our lives. Sleep refers to a state in which conscious activity rests with eyes closed, and is an important process to replenish the energy used by a person while active during the day and to recover from fatigue accumulated by physical activity. Sleep is not only a time to recover from energy and fatigue, but also to secrete the most growth hormone, which is essential for human growth. In our body, the brain oversees all physiological functions for life support, and in order for the brain to maintain a proper balance of activities, rest is essential, and most of these breaks occur during sleep.
그러나 현대인들은 업무과다, 스트레스 증가, 노령화, 교통의 발달(수면주기변화), 생활환경 및 질환 등의 다양한 원인으로 성인 중 10% 이상이 수면 장애를 호소하며 성인의 1/3 정도는 일생 동안 어떤 형태로든 수면 장애를 경험한다고 한다. 수면 장애는 흔히 신경정신질환의 초기 증상으로 나타나며 일부 정신질환은 수면생리의 특징적인 변화를 동반한다. '국민건강보험공단'의 분석 결과에 따르면, 2006~2015년 국내 수면장애 환자는 약 15만명(2006년)에서 약 46만명(2015년)으로 10년 사이 209%나 증가하였고, 10대 및 20대의 경우에도 10년 사이 수면 장애를 겪고 있는 환자가 2배 가량 늘어난 것으로 나타났다.
However, in modern people, more than 10% of adults complain of sleep disorders due to various causes such as overwork, increased stress, aging, development of transportation (changes in sleep cycle), living environment and diseases, and about one third of adults have some problems during their lifetime. They are said to experience sleep disturbances in some form. Sleep disturbances often appear as early symptoms of neuropsychiatric disorders, and some mental disorders are accompanied by characteristic changes in sleep physiology. According to the analysis results of'National Health Insurance Corporation', the number of sleep disorder patients in Korea from 2006 to 2015 increased from about 150,000 (2006) to about 460,000 (2015), an increase of 209% in 10 years, and in teens and 20s. Even in the case of teens, the number of patients suffering from sleep disturbances in 10 years increased by about 2 times.
현재 상용되는 대표적 항불안제는 벤조디아제핀(benzodiazepine), 디아제팜(diazepam), 옥사제팜(oxazepam), 프라제팜(prazepam), 로라제팜(lorazepam), 알프라졸람(alprazolam), 헬라제팜(helazepam), 클로나제팜(clonazepam) 등이 있으며, 이들 약물들은 주로 진정 및 수면유도의 목적으로도 사용된다. 이중 벤조디아제핀은 가장 흔히 사용하는 항불안제로, 효과가 즉각 나타나지만 습관성과 중독성이 단점으로 전문의의 치료에 따라 약을 사용하지 않으면 증상이 재발하거나 금단증상이 나타나며, 다른 부작용으로 졸음, 운동실조, 기립성 저혈압, 호흡 억제, 두통, 만성수면장애, 간질환 등이 나타난다고 보고되고 있다. 이처럼 현재 신경안정을 위하여 불안과 수면장애 치료를 위해 많이 사용되고 있는 약물들은 장기 복용에 의해 내성과 의존성이 생기며, 기억 감퇴, 감각기능의 마비, 호흡기능의 억제와 같은 부작용을 동반하는 것으로 알려져 있고, 민간요법의 경우, 그 효능 검증의 기준이 적절하게 마련되어 있지 않아 객관적인 효능 평가가 어려운 단점이 있다. 따라서, 이런 불안증과 수면장애 개선할 수 있는 신경안정제를 대체하기 위하여 생약을 이용한 천연의약품에 대한 필요성이 대두되고 있다.
Representative anti-anxiety drugs currently in use are benzodiazepine, diazepam, oxazepam, prazepam, lorazepam, alprazolam, helazepam, clonazepam. (clonazepam), and these drugs are mainly used for sedation and sleep induction. Among them, benzodiazepines are the most commonly used anti-anxiety agents, and their effects appear immediately, but their habits and addiction are disadvantages. If the drug is not used according to the treatment of a specialist, symptoms recur or withdrawal symptoms appear, and other side effects include drowsiness, ataxia, orthostatic hypotension. , Respiratory depression, headache, chronic sleep disorder, liver disease, etc. are reported to occur. As such, drugs that are currently widely used for the treatment of anxiety and sleep disorders for nervous stability are known to have side effects such as memory loss, paralysis of sensory function, and suppression of respiratory function, and resistance and dependence are created by long-term use. In the case of folk remedies, there is a disadvantage that objective evaluation of efficacy is difficult because the criteria for verifying the efficacy are not properly established. Therefore, there is a need for natural medicines using herbal medicines in order to replace tranquilizers that can improve anxiety and sleep disorders.
이에 본 발명자들은 천연물 유래 수면 장애 치료제를 개발하기 위해 노력한 결과, 상추(Lactuca sativa) 및 황금(Scutellaria baicalensis) 복합 추출물을 분말 과립으로 제조 시 용해도가 우수하고, 용해하여 음용 시 쓴맛이 거의 없으며 추출물 특유의 향을 마스킹하고 우수한 수면 증진 효과가 있음을 확인함으로써, 상기 상추 및 황금 복합 추출물을 수면 장애 예방 또는 치료용 조성물, 또는 수면 질 개선, 및 일주기 리듬 변화를 위한 조성물, 또는 건강식품으로 사용할 수 있음을 밝힘으로써, 본 발명을 완성하였다.
Accordingly, the present inventors endeavored to develop a natural product-derived treatment for sleep disorders, as a result, lettuce ( Lactuca sativa ) and golden ( Scutellaria) baicalensis ) When the complex extract is prepared as powdered granules, it has excellent solubility, has little bitter taste when consumed by dissolving, masks the unique scent of the extract, and has an excellent sleep-promoting effect, thereby preventing sleep disorders with the lettuce and golden complex extract. Or a therapeutic composition, or a composition for improving sleep quality, and a circadian rhythm change, or by revealing that it can be used as a health food, the present invention was completed.
본 발명의 목적은 상추(Lactuca sativa) 및 황금(Scutellaria baicalensis) 복합 추출물을 유효성분으로 함유하는 수면 질환 또는 수면 장애 예방 또는 치료용 약학적 조성물을 제공하기 위한 것이다.The object of the present invention is lettuce ( Lactuca sativa ) and golden ( Scutellaria) baicalensis ) It is to provide a pharmaceutical composition for preventing or treating sleep disorders or sleep disorders containing a complex extract as an active ingredient.
본 발명의 다른 목적은 상추 및 황금 복합 추출물을 유효성분으로 함유하는 수면 질환 또는 수면 장애 예방 또는 개선용 건강식품을 제공하기 위한 것이다.
Another object of the present invention is to provide a health food for preventing or improving sleep disorders or sleep disorders containing a lettuce and golden complex extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 상추(Lactuca sativa) 및 황금(Scutellaria baicalensis) 복합 추출물을 유효성분으로 함유하는 수면 질환 또는 수면 장애 예방 또는 치료용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention is lettuce ( Lactuca sativa ) and golden ( Scutellaria baicalensis ) It provides a pharmaceutical composition for preventing or treating sleep disorders or sleep disorders containing a complex extract as an active ingredient.
또한, 본 발명은 상추 및 황금 복합 추출물을 유효성분으로 함유하는 수면 질환 또는 수면 장애 예방 또는 개선용 식품, 건강식품을 제공한다.In addition, the present invention provides a food, health food for preventing or improving sleep disorders or sleep disorders containing the lettuce and golden complex extract as an active ingredient.
또한, 본 발명은 상추 및 황금 복합 추출물을 유효성분으로 함유하는 수면 질 개선용, 일주기 리듬 변화용 식품, 건강식품을 제공한다. In addition, the present invention provides a sleep quality improvement, circadian rhythm change food, health food containing lettuce and golden complex extract as an active ingredient.
아울러, 본 발명은 In addition, the present invention
1) 상추 추출물 분말 및 황금 추출물 분말을 혼합하여 복합 추출물 분말을 제조하는 단계;1) preparing a composite extract powder by mixing the lettuce extract powder and the golden extract powder;
2) 단계 1)의 복합 추출물 분말 및 당류를 혼합하여 시드(seed)를 제조하는 단계; 및2) preparing a seed by mixing the complex extract powder and sugars of step 1); And
3) 단계 2)의 시드를 유동층 과립기의 내부에 첨가하여 유동화하고, 물을 분사하여 당류가 코팅된 복합 추출물 분말 과립을 수득하는 단계를 포함하는, 상추 및 황금 복합 추출물 분말 과립의 제조방법 및 상기 방법으로 제조된 상추 및 황금 복합 추출물 분말 과립을 제공한다.
3) adding the seed of step 2) to the inside of the fluidized bed granulator to fluidize, and spraying water to obtain a saccharide-coated complex extract powder granules, a method for producing a lettuce and golden complex extract powder granules, and It provides a lettuce and golden complex extract powder granules prepared by the above method.
본 발명의 상추(Lactuca sativa) 및 황금(Scutellaria baicalensis) 복합 추출물은 분말 과립으로 제조 시 용해도가 우수하고, 용해하여 음용 시 쓴맛이 거의 없으며 추출물 특유의 향을 마스킹하고 우수한 수면 증진 효과를 나타내므로, 불면증, 기면증, 수면 중 이상행동, 과수면증 등을 포함하는 수면 질환 또는 수면 장애 예방 또는 치료용 조성물, 또는 수면 질 개선, 일주기 리듬 변화를 위한 조성물, 또는 건강식품으로 유용하게 사용될 수 있다.
Lettuce (Lactuca sativa ) and golden ( Scutellaria ) of the present invention baicalensis ) Complex extract has excellent solubility when prepared as powdered granules, has little bitter taste when dissolved and consumed, masks the unique scent of the extract and exhibits excellent sleep enhancement effect, so insomnia, narcolepsy, abnormal behavior during sleep, hypersomnia It may be usefully used as a composition for preventing or treating a sleep disorder or a sleep disorder, including the like, or a composition for improving sleep quality, a circadian rhythm change, or a health food.
이하 본 발명을 상세히 설명한다.
Hereinafter, the present invention will be described in detail.
본 발명은 상추(Lactuca sativa) 및 황금(Scutellaria baicalensis) 복합 추출물을 유효성분으로 함유하는 수면 질환 또는 수면 장애 예방 또는 치료용 약학적 조성물을 제공한다.The present invention is lettuce ( Lactuca sativa ) and golden ( Scutellaria) baicalensis ) It provides a pharmaceutical composition for preventing or treating sleep disorders or sleep disorders containing a complex extract as an active ingredient.
상기 복합 추출물은 하기의 단계들을 포함하는 방법에 의해 제조되는 것이 바람직하나, 이에 한정되지 않는다: The complex extract is preferably prepared by a method comprising the following steps, but is not limited thereto:
a) 상추 및 황금 각각에 추출용매를 가하여 추출하는 단계;a) extracting by adding an extraction solvent to each of lettuce and gold;
b) 단계 a)의 추출물 각각을 여과하는 단계;b) filtering each of the extracts of step a);
c) 단계 b)의 여과물 각각을 감압 농축하는 단계; 및c) concentrating each filtrate of step b) under reduced pressure; And
d) 단계 c)의 농축물 각각을 건조하고 혼합하는 단계.d) drying and mixing each of the concentrates of step c).
본 발명의 제조방법에 있어서, 단계 a)의 상추 및 황금은 재배한 것 또는 시판되는 것을 제한 없이 사용할 수 있다.In the production method of the present invention, lettuce and gold in step a) can be used without limitation, grown or commercially available.
본 발명의 제조방법에 있어서, 상기 단계 a)의 추출용매는 물, 알코올 또는 이의 혼합물을 사용하는 것이 바람직하다. 상기 알코올로는 C1 내지 C2의 저급 알코올 이용하는 것이 바람직하며, 저급 알코올로는 에탄올 또는 메탄올을 이용하는 것이 바람직하다. 추출방법으로는 진탕추출, Soxhelt 추출 또는 환류 추출을 이용하는 것이 바람직하나, 이에 한정하지 않는다. 상기 추출용매를 건조된 상추 또는 황금 분량의 6 내지 12배 첨가하여 추출하는 것이 바람직하며, 8 내지 10배 첨가하여 추출하는 것이 더욱 바람직하다. 추출 온도는 20℃ 내지 100℃인 것이 바람직하며, 80℃ 내지 90℃인 것이 가장 바람직하나, 이에 한정하지 않는다. 또한, 추출시간은 1 내지 24시간이 바람직하며, 2 내지 10시간이 더욱 바람직하고, 3 내지 5시간이 가장 바람직하나, 이에 한정하지 않는다. 아울러 추출 횟수는 1 내지 3회인 것이 바람직하나, 이에 한정되는 것은 아니다. In the production method of the present invention, it is preferable to use water, alcohol, or a mixture thereof as the extraction solvent in step a). It is preferable to use C 1 to C 2 lower alcohol as the alcohol, and it is preferable to use ethanol or methanol as the lower alcohol. The extraction method is preferably shaking extraction, Soxhelt extraction, or reflux extraction, but is not limited thereto. It is preferable to extract by adding the extraction solvent 6 to 12 times the amount of dried lettuce or gold, and more preferably to extract by adding 8 to 10 times. The extraction temperature is preferably from 20°C to 100°C, and most preferably from 80°C to 90°C, but is not limited thereto. In addition, the extraction time is preferably 1 to 24 hours, more preferably 2 to 10 hours, and most preferably 3 to 5 hours, but is not limited thereto. In addition, the number of extractions is preferably 1 to 3 times, but is not limited thereto.
본 발명의 제조방법에 있어서, 단계 c)의 감압농축은 진공 감압 농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정하지 않는다. In the production method of the present invention, the vacuum concentration in step c) is preferably a vacuum vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto.
본 발명의 제조방법에 있어서, 단계 d)의 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조하는 것이 바람직하고, 분무건조하는 것이 더욱 바람직하나, 이에 한정하지 않는다. 건조 온도는 100 내지 200℃인 것이 바람직하고, 160 내지 180℃인 것이 더욱 바람직하나, 이에 한정하지 않는다. 또한, 상추 및 황금 건조물 각각을 1 : 0.5 내지 2의 중량비로 배합하는 것이 바람직하나, 이에 한정되는 것은 아니다.In the manufacturing method of the present invention, the drying in step d) is preferably vacuum drying, vacuum drying, boiling drying, spray drying or freeze drying, and more preferably spray drying, but is not limited thereto. The drying temperature is preferably 100 to 200°C, more preferably 160 to 180°C, but is not limited thereto. In addition, it is preferable to mix each of lettuce and dried golden matter in a weight ratio of 1: 0.5 to 2, but is not limited thereto.
상기 상추 및 황금 복합 추출물은 과립화된 분말 과립으로 제형화될 수 있다. 상기 분말 과립은 용해도가 우수하고, 용해하여 음용 시 쓴맛이 거의 없으며 추출물 특유의 향을 마스킹하여 기호도가 우수하다.The lettuce and golden complex extract may be formulated into granulated powder granules. The powder granules have excellent solubility, almost no bitter taste when dissolved and consumed, and excellent palatability by masking the unique scent of the extract.
상기 분말 과립은 하기의 단계들을 포함하는 방법에 의해 과립화될 수 있으나, 이에 제한되지 않는다:The powder granules may be granulated by a method comprising the following steps, but is not limited thereto:
1) 상추 추출물 분말 및 황금 추출물 분말을 혼합하여 복합 추출물 분말을 제조하는 단계;1) preparing a composite extract powder by mixing the lettuce extract powder and the golden extract powder;
2) 단계 1)의 복합 추출물 분말 및 당류를 혼합하여 시드(seed)를 제조하는 단계; 및2) preparing a seed by mixing the complex extract powder and sugars of step 1); And
3) 단계 2)의 시드를 유동층 과립기의 내부에 첨가하여 유동화하고, 물을 분사하여 당류가 코팅된 복합 추출물 분말 과립을 수득하는 단계.3) adding the seed of step 2) to the inside of the fluidized bed granulator for fluidization, and spraying water to obtain granules of complex extract powder coated with sugars.
본 발명의 제조방법에 있어서, 상기 단계 1)에서 상추 추출물 분말 및 황금 추출물 분말을 1 : 0.5 내지 2의 중량비로 혼합하는 것이 바람직하나, 이에 한정하지 않는다.In the manufacturing method of the present invention, it is preferable to mix the lettuce extract powder and the golden extract powder in a weight ratio of 1: 0.5 to 2 in step 1), but is not limited thereto.
본 발명의 제조방법에 있어서, 상기 단계 2)에서 복합 추출물 분말 및 당류를 1 : 1.0 내지 3.5의 중량비로 혼합하는 것이 바람직하고, 1 : 1.5 내지 3.0의 중량비로 혼합하는 것이 보다 바람직하나, 이에 한정하지 않는다. 또한, 상기 복합 추출물 분말을 15 내지 25 중량부, 당류를 15 내지 75 중량부로 혼합할 수 있다. 상기 당류는 예를 들어 무수결정포도당, 함수결정포도당, 과당, 말토스, 슈크로스, 올리고당, 덱스트린, 사이클로덱스트린, 자이리톨, 소르비톨, 에리스리톨, 팔라티노스, 트레할로스, 스테비오사이드, 수크랄로스, 아스파탐 또는 아세파탐 칼륨일 수 있고, 구체적으로 과당일 수 있으나, 이에 제한하지 않는다. 상기 복합 추출물 분말 및 당류를 혼합하고 입자크기를 균일화하기 위해 당업계에 공지된 다양한 믹서기 및 분쇄기를 이용할 수 있다.In the production method of the present invention, it is preferable to mix the complex extract powder and the saccharide in a weight ratio of 1: 1.0 to 3.5 in step 2), and more preferably to mix in a weight ratio of 1: 1.5 to 3.0, but limited thereto. I never do that. In addition, 15 to 25 parts by weight of the composite extract powder, and 15 to 75 parts by weight of saccharides may be mixed. The saccharides are, for example, anhydrous crystalline glucose, hydrous crystalline glucose, fructose, maltose, sucrose, oligosaccharide, dextrin, cyclodextrin, xylitol, sorbitol, erythritol, palatinose, trehalose, stevioside, sucralose, aspartame or acepartame. It may be potassium, specifically, fructose, but is not limited thereto. Various blenders and pulverizers known in the art may be used to mix the complex extract powder and sugars and uniformize the particle size.
본 발명의 제조방법에 있어서, 상기 단계 3)은 유동층 과립기의 흡입공기온도 50 내지 80℃의 조건, 배기온도 30 내지 40℃의 조건에서 실시될 수 있다.In the manufacturing method of the present invention, the step 3) may be carried out under conditions of 50 to 80°C intake air temperature and 30 to 40°C for exhaust temperature of the fluidized bed granulator.
상기 수면 질환 또는 수면 장애는 불면증, 기면증, 수면 중 이상행동 또는 과수면증일 수 있으나, 수면과 관련된 질환이면 이에 제한되지는 않는다.The sleep disorder or sleep disorder may be insomnia, narcolepsy, abnormal behavior during sleep, or hypersomnia, but is not limited thereto if it is a sleep-related disorder.
본 발명에서 상기 "불면증"은 가장 대표적인 수면 장애 증상으로, 잠자리에 누워도 잠들기 어려운 입면 장애, 하룻밤 동안 잠을 깨는 횟수가 5회 이상인 수면유지 장애, 일찍 잠을 깨서 다시 잠들지 못하는 조기각성 장애로 구별될 수 있다.In the present invention, the "insomnia" is the most representative symptom of sleep disorder, which is distinguished by a sleep disorder in which it is difficult to fall asleep even when lying in bed, a sleep maintenance disorder in which the number of times awakening during the night is 5 or more, and an early arousal disorder in which a person cannot fall asleep again after waking up early. Can be.
본 발명에서 상기 "기면증"은 렘(REM) 수면의 비정상적인 발현으로 인한 수면 장애 질환으로, 주된 증상인 주간 과다 졸림증(excessive daytime sleepness) 외에, 크게 웃거나 화를 내는 등 감정의 자극이 있을 때 몸의 힘이 갑자기 빠지는 허탈발작(cataplexy), 잠에 들거나 깰 때 머리는 깨어 있으나 몸을 움직일 수 없는 수면 마비(sleep paralysis), 잠에 들거나 잠에서 깰 때 꿈이 현실로 이행되어 보이는 입면환각(hypnagogic hallucination) 등이 동반되어 나타난다.In the present invention, the "narrosis" is a sleep disorder disease caused by abnormal expression of REM sleep. In addition to the main symptom, excessive daytime sleepness, the body Cataplexy, in which the power of a person suddenly falls asleep, sleep paralysis, in which the head is awake but the body cannot move when falling asleep or awakening, and hyponagogic in which dreams become reality when falling asleep or awakening. hallucination).
본 발명에서 상기 "수면 중 이상행동"은 하지불안증후군, 가위눌림, 악몽, 렘수면 장애, 수면 보행증(몽유병), 야경증 등과 같이 정상적인 경우 수면 중에 나타나지 않는 움직임이나 행동이 나타나는 증상으로, 특히 하지불안증후군은 다리에 나타나는 스멀거림이나 저림증 같은 불쾌한 감각으로 인해 다리를 움직이고 싶은 충동을 느끼며 때로는 충동을 참을 수 없어 수면 중에 다리를 떨거나 꿈틀거려야만 하는 증상이다.In the present invention, the "abnormal behavior during sleep" is a symptom of movement or behavior that does not appear during sleep in normal cases, such as restless legs syndrome, pressed scissors, nightmares, REM sleep disorder, sleep walking (sleepwalking), night view, etc. Syndrome is a symptom in which you feel the urge to move your legs due to unpleasant sensations such as tingling or tingling in your legs, and sometimes you can't stand the urge and you have to shake or wriggle your legs during sleep.
본 발명에서 상기 "과수면증"은 렘(REM) 수면의 비정상적인 발현과는 상관없이, 밤 중 깊은 잠에 들지 못해 충분한 수면 시간을 취했음에도 낮에 계속 졸음이 몰려와 일상생활에 지장을 받을 정도의 상태를 일컫는 수면 장애이다. 기면증과 달리 잠에 빠지는 것을 본인이 인지하지 못하고 갑자기 잠이 드는 '수면발작' 증상은 나타나지 않는다.
In the present invention, the "hypersomnia" refers to an abnormal expression of REM sleep, regardless of the abnormal manifestation of REM sleep, so that even though a person cannot fall asleep deeply during the night and has taken sufficient sleep time, sleepiness continues to flow during the day, causing difficulties in daily life. It is a sleep disorder that refers to the condition of. Unlike narcolepsy, there are no symptoms of ``sleeping seizures,'' in which the person suddenly falls asleep without being aware of falling asleep.
본 발명의 구체적인 실시예에서, 본 발명자들은 상추 및 황금 복합 추출물을 제조한 후, 이의 용해도를 높이기 위해 유동층 과립 공정을 통해 복합 추출물 분말 과립을 제조하였다. 또한, 상기 분말 과립 제조 공정에서 복합 추출물 분말 및 결정과당을 1 : 1.5 내지 3.0의 중량비로 혼합할 경우 제조된 복합 추출물 분말 과립의 용해도가 현저히 우수함을 확인하였다. 아울러, 상기 용해도가 우수한 복합 추출물 분말 과립을 이용하여 관능평가를 수행한 결과, 음용 시 쓴맛이 거의 없고, 향의 거부감이 없으며, 이에 종합적 기호도가 우수함을 확인하였다.In a specific embodiment of the present invention, the present inventors prepared the lettuce and golden composite extract, and then prepared the composite extract powder granules through a fluidized bed granulation process in order to increase the solubility thereof. In addition, it was confirmed that the solubility of the prepared composite extract powder granules was remarkably excellent when the composite extract powder and the crystal fructose were mixed in a weight ratio of 1: 1.5 to 3.0 in the powder granule manufacturing process. In addition, as a result of performing a sensory evaluation using the complex extract powder granules having excellent solubility, it was confirmed that there is little bitter taste when drinking, there is no rejection of aroma, and thus, overall acceptability is excellent.
또한, 상기 용해도가 우수한 복합 추출물 분말 과립을 이용하여 수면의 질을 평가한 결과, 상기 복합 추출물 분말 과립을 용해하여 복용한 피험자의 수면의 질이 개선되는 것을 확인하였다.In addition, as a result of evaluating the quality of sleep using the complex extract powder granules having excellent solubility, it was confirmed that the sleep quality of the subject who took the complex extract powder granules dissolved and taken was improved.
따라서, 본 발명의 상추 및 황금 복합 추출물의 분말 과립은 용해도 우수하고, 섭취의 거부감이 없으며, 수면 증진 효능이 우수하므로, 상기 상추 및 황금 복합 추출물을 수면 질환 또는 수면 장애 예방 또는 치료용 조성물의 유효성분으로 유용하게 이용할 수 있다.
Therefore, the powdered granules of the lettuce and golden complex extract of the present invention are excellent in solubility, there is no rejection of intake, and the sleep promoting effect is excellent, so that the lettuce and golden complex extract is effective in the composition for preventing or treating sleep disorders or sleep disorders. It can be usefully used as an ingredient.
본 발명의 조성물은 경구 또는 비경구 투여(예를 들어, 도포 또는 정맥 내, 피하, 복강 내 주사)할 수 있으나 경구 투여가 바람직하다. 비경구 투여를 위한 제제로는 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 멸균된 수용액, 액제, 비수성용제, 현탁제, 에멀젼, 시럽, 좌제, 에어로졸 등의 외용제 및 멸균 주사제제의 형태로 제형화하여 사용될 수 있으며, 바람직하게는 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플 라스마제의 피부 외용 약학적 조성물을 제조하여 사용할 수 있으나, 이에 한정하는 것은 아니다. 국소 투여의 조성물은 임상적 처방에 따라 무수형 또는 수성형일 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. 경구 투여를 위한 고형제제에는 산제, 과립제, 정제, 캡슐제, 연질캅셀제, 환 등이 포함된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제, 에어로졸 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.The composition of the present invention may be administered orally or parenterally (eg, application or intravenous, subcutaneous, intraperitoneal injection), but oral administration is preferred. Formulations for parenteral administration include powders, granules, tablets, capsules, sterilized aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, syrups, suppositories, aerosols, etc. Formulated in a form and used, preferably, a pharmaceutical composition for skin external use of cream, gel, patch, spray, ointment, warning agent, lotion, linerment, pasta or cataplasma may be prepared and used. However, it is not limited thereto. Compositions for topical administration may be anhydrous or aqueous, depending on the clinical prescription. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used. Solid preparations for oral administration include powders, granules, tablets, capsules, soft capsules, pills, and the like. Liquid preparations for oral use include suspensions, solvents, emulsions, syrups, aerosols, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as humectants, sweeteners, fragrances, and preservatives are included I can.
상기 조성물은 투여를 위해서 상추 및 황금 복합 추출물 유효성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 제조할 수 있다. 약제학적으로 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형 등으로 제제화할 수 있다.The composition may be prepared by including one or more pharmaceutically acceptable carriers in addition to the active ingredients of the lettuce and golden complex extract for administration. Pharmaceutically acceptable carriers can be used by mixing saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components, and if necessary, antioxidants and buffers. , Other conventional additives such as bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to form an injectable formulation such as an aqueous solution, suspension, or emulsion.
본 발명에 따른 약제학적으로 허용가능한 첨가제는 상기 조성물에 대해 0.1~90 중량부 포함되는 것이 바람직하다.The pharmaceutically acceptable additive according to the present invention is preferably contained in an amount of 0.1 to 90 parts by weight based on the composition.
본 발명의 조성물의 바람직한 투여량은 체내에서 활성성분의 흡수도, 환자의 연령, 성별 및 비만의 정도에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 경구 투여제의 경우 일반적으로 성인에게 1일에 체중 1㎏당 본 발명의 조성물을 1일 0.0001 내지 100 ㎎/㎏으로, 바람직하게는 0.001 내지 100 ㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the composition of the present invention depends on the degree of absorption of the active ingredient in the body, the age, sex, and degree of obesity of the patient, but may be appropriately selected by those skilled in the art. However, for a desirable effect, in the case of oral administration, it is generally recommended to administer the composition of the present invention to adults at 0.0001 to 100 mg/kg per day, preferably 0.001 to 100 mg/kg per 1 kg of body weight per day. good. Administration may be administered once a day, or may be divided several times. The above dosage does not limit the scope of the present invention in any way.
본 발명의 조성물은 상추 및 황금 복합 추출물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다.
The composition of the present invention may contain one or more active ingredients showing the same or similar function in addition to the lettuce and golden complex extract.
본 발명은 상추 및 황금 복합 추출물을 유효성분으로 함유하는, 수면 질환 또는 수면 장애 예방 또는 개선용 식품, 건강식품을 제공한다.The present invention provides food, health food for preventing or improving sleep disorders or sleep disorders, containing lettuce and golden complex extract as an active ingredient.
또한, 본 발명은 상추 및 황금 복합 추출물을 유효성분으로 함유하는, 수면 질 개선용, 일주기 리듬 변화용 식품, 건강식품을 제공한다.In addition, the present invention provides a food, health food for improving sleep quality, circadian rhythm change, containing lettuce and golden complex extract as an active ingredient.
상기 상추 및 황금 복합 추출물은 상기 수면 질환 또는 수면 장애 예방 또는 치료용 조성물에 대한 설명과 동일한 바, 구체적인 설명은 상기 내용을 원용하고, 이하에서는 식품 또는 건강식품에 특유한 구성에 대해서만 설명하도록 한다.The lettuce and golden complex extract is the same as the description of the composition for preventing or treating sleep disorders or sleep disorders, and the specific description uses the above, and hereinafter, only the composition specific to food or health food will be described.
한편, 약학적 조성물과 마찬가지로, 본 발명의 상추 및 황금 복합 추출물의 분말 과립은 용해도 우수하고, 섭취의 거부감이 없으며, 수면 증진 효능이 우수하므로, 상기 상추 및 황금 복합 추출물을 수면 질환 또는 수면 장애 예방 또는 개선, 수면 질 개선, 일주기 리듬 변화용 식품, 건강식품의 유효성분으로 유용하게 사용될 수 있다.
On the other hand, like the pharmaceutical composition, the powdered granules of the lettuce and golden complex extract of the present invention are excellent in solubility, there is no rejection of ingestion, and the sleep promoting effect is excellent, so that the lettuce and golden complex extract prevent sleep disorders or sleep disorders. Or it can be usefully used as an active ingredient for improvement, sleep quality improvement, circadian rhythm change food, and health food.
본 발명의 상추 및 황금 복합 추출물을 식품 또는 음료 첨가물로 사용할 경우, 상기 상추 및 황금 복합 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용되고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 상기 상추 및 황금 복합 추출물의 혼합양은 그의 사용목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 건강 및 위생을 목적으로 하거나 또는 건강조절을 목적으로 하는 장기간의 섭취의 경우, 상기 상추 및 황금 복합 추출물은 안전성 면에서 아무런 문제가 없기 때문에, 장기간 복용이 가능하다. 상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿류, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있다. 음료수로 제형화할 경우에 상추 및 황금 복합 추출물 이외에 첨가되는 액체 성분으로는 이제 한정되지는 않으나, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드(예, 포도당, 과당 등), 디사카라이드(예, 말토오스, 수크로오스 등) 및 폴리사카라이드(예, 덱스트린, 시클로덱스트린 등과 같은 통상적인 당), 및 자일리톨, 소르비톨, 에리스리톨 등의 당 알코올이다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖ 당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다. 상술한 것 이외의 향미제로서 천연 향미제[타우마린, 스테비아 추출물(예, 레바우디오시드 A, 글리시르히진 등)] 및 합성 향미제(예, 사카린, 아스파르탐 등)를 사용할 수 있다.
When the lettuce and golden complex extract of the present invention is used as a food or beverage additive, the lettuce and golden complex extract are added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixed amount of the lettuce and golden complex extract may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment). In the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the lettuce and golden compound extract have no problem in terms of safety, and thus can be taken for a long time. There is no particular limitation on the type of the food. Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, and drinks. , Alcoholic beverages and vitamin complexes. When formulated as a beverage, the liquid component added in addition to the lettuce and golden complex extract is not limited anymore, but may contain various flavoring agents or natural carbohydrates as an additional component, such as in a conventional beverage. Examples of the above-described natural carbohydrates are monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.) and polysaccharides (e.g., common sugars such as dextrin, cyclodextrin, etc.), and xylitol. , Sorbitol, and sugar alcohols such as erythritol. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention. As flavoring agents other than those described above, natural flavoring agents [taumarin, stevia extract (eg, rebaudioside A, glysirhizin, etc.)] and synthetic flavoring agents (eg, saccharin, aspartame, etc.) can be used. .
또한, 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 증진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 또한 본 발명의 식품 조성물은 과일 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 단독으로 또는 조합으로 사용될 수 있으며, 이러한 첨가제의 비율은 조성물 전체 중량당 0.001 내지 50 중량부의 범위에서 선택되는 것이 일반적이다.
In addition, the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic flavors and flavoring agents such as natural flavors, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, organic acids, protection It may contain a colloidal thickener, a pH adjuster, a stabilizer, a preservative, a glycerin, an alcohol, a carbonation agent used in carbonated beverages, and the like. In addition, the food composition of the present invention may contain pulp for the production of fruit and vegetable beverages. These components may be used alone or in combination, and the proportion of these additives is generally selected in the range of 0.001 to 50 parts by weight per total weight of the composition.
이하 본 발명의 실시예, 실험예 및 제조예에 의해 상세히 설명한다.Hereinafter, it will be described in detail with reference to Examples, Experimental Examples and Preparation Examples of the present invention.
단, 하기 실시예, 실험예 및 제조예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예, 실험예 및 제조예에 한정되는 것은 아니다.
However, the following Examples, Experimental Examples, and Preparation Examples are merely illustrative of the present invention, and the contents of the present invention are not limited to the following Examples, Experimental Examples, and Preparation Examples.
<< 실시예Example 1> 상추 추출물 및 황금 추출물의 제조 1> Preparation of lettuce extract and golden extract
90% 이상의 수분함량을 갖는 상추(Lactuca sativa)의 수분함량을 5% 이하가 되도록 17시간 동안 건조한 후 분쇄하였다. 분쇄한 상추 건조물에 9배수의 70% 에탄올을 넣고 85℃에서 4시간 동안 2회 분할 추출 및 여과한 후, 30 내지 35 brix로 감압농축하고 170℃에서 분무건조 하여 70% 에탄올 추출물 분말을 얻었다. The moisture content of lettuce (Lactuca sativa ) having a moisture content of 90% or more was dried for 17 hours to be less than 5%, and then pulverized. After 9 times of 70% ethanol was added to the pulverized lettuce dried product, extracted and filtered twice at 85°C for 4 hours, concentrated under reduced pressure at 30 to 35 brix, and spray dried at 170°C to obtain a 70% ethanol extract powder.
또한, 시판되는 황금(Scutellaria baicalensis) 건조물을 절각하고, 절각한 황금 건조물에 9배수의 70% 에탄올을 넣고 85℃에서 4시간 동안 2회 분할 추출 및 여과한 후, 30 내지 35 brix로 감압농축하고 170℃에서 분무건조 하여 70% 에탄올 추출물 분말을 얻었다.
Also, commercially available gold ( Scutellaria baicalensis ) The dried product was cut, 9 times of 70% ethanol was added to the cut gold dried product, extracted and filtered twice for 4 hours at 85°C, concentrated under reduced pressure with 30 to 35 brix, spray dried at 170°C, and 70 % Ethanol extract powder was obtained.
<< 실시예Example 2> 상추 및 황금 복합 추출물 분말 과립의 제조 2> Preparation of lettuce and golden complex extract powder granules
에탄올 추출물은 물에 잘 용해되지 않고 서로 뭉치는 단점이 있다. 이러한 단점을 개선하기 위해 상추 및 황금 복합 추출물 분말을 결정과당으로 코팅하고 과립화 하였다. Ethanol extracts do not dissolve well in water and have the disadvantage of clumping together. In order to improve these shortcomings, lettuce and golden complex extract powders were coated with fructose and granulated.
구체적으로, 상기 <실시예 1>에서 제조한 상추 에탄올 추출물 분말 및 황금 에탄올 추출물을 1 : 1 비율로 혼합하여 상추 및 황금 복합 추출물 분말을 제조하였다. 그 다음, 제조한 상추 및 황금 복합 추출물 분말 18 중량%와 결정과당 36 중량%를 혼합하고, 이를 흡입공기온도가 50 내지 80℃이고, 배기온도가 30 내지 40℃인 배치타입(batch type) 유동층 과립기로 옮겨서 유동층 과립기 내부에서 상기 혼합물을 유동화시키면서 정제수를 총 3회 분사기를 통해 유동화에 분사시켰다. 이에 따라 결정과당이 상추 및 황금 복합 추출물 분말에 코팅된 상추 및 황금 복합 추출물 분말 과립을 수득하였다.
Specifically, lettuce and golden composite extract powder were prepared by mixing the lettuce ethanol extract powder and golden ethanol extract prepared in <Example 1> in a 1:1 ratio. Then, 18% by weight of the prepared lettuce and golden complex extract powder and 36% by weight of crystal fructose are mixed, and the intake air temperature is 50 to 80°C, and the exhaust temperature is 30 to 40°C. Transferred to the granulator, while fluidizing the mixture inside the fluidized bed granulator, purified water was sprayed into the fluidization through a sprayer for a total of three times. Accordingly, lettuce and golden complex extract powder granules coated with crystal fructose on lettuce and golden complex extract powder were obtained.
<< 실험예Experimental example 1> 상추 및 황금 복합 추출물 분말 과립의 용해도 확인 1> Check the solubility of lettuce and golden complex extract powder granules
과립 제조 시 상추 및 황금 복합 추출물 분말과 결정과당의 혼합 비율에 달리하여 제조한 본 발명의 복합 추출물 분말 과립의 용해도를 확인하기 위하여, 분산성 및 침전성을 분석하였다.In order to confirm the solubility of the granules of the composite extract powder of the present invention prepared by varying the mixing ratio of the lettuce and golden composite extract powder and the crystal fructose during granulation production, dispersibility and sedimentation properties were analyzed.
구체적으로, 상기 <실시예 2>에 기재된 방법과 동일한 방법으로 진행하되, 상추 및 황금 복합 추출물 분말 18 중량%에 결정과당을 1 : 1 (#1), 1 : 1.5 (#2), 1 : 2 (#3), 1 : 2.5 (#4) 및 1 : 3 (#5)의 중량% 비율로 혼합하여 상추 및 황금 복합 추출물 분말 과립을 제조하였다.Specifically, proceed in the same manner as described in the <Example 2>, but the crystalline fructose in 18% by weight of lettuce and golden complex extract powder 1: 1 (#1), 1: 1.5 (#2), 1: 2 (#3), 1: 2.5 (#4) and 1: 3 (#5) by mixing in a weight% ratio of lettuce and golden complex extract powder granules were prepared.
그 다음, 분산성을 분석하기 위하여, 상기 복합 추출물 분말 과립 각각을 마시는 물 100 ㎖에 10 g씩 첨가하고 섞은 다음 실온에서 10분 동안 방치한 후 스펙트로포토미터(spectrophotometer)로 450 mn에서 흡광도를 측정하고, 하기 [수학식 1]을 이용하여 투광도(T%)를 계산하였다. 이 때 투광도는 시료의 농도와 무관하기 때문에 배합 비율에 따른 농도 편차 오류를 배제할 수 있다. 또한, 투광도가 10인 경우 90%의 빛이 시료를 통과하지 못함을 의미한다.Then, in order to analyze the dispersibility, 10 g of each of the complex extract powder granules was added to 100 ml of drinking water, mixed, and allowed to stand at room temperature for 10 minutes, and the absorbance was measured at 450 mn with a spectrophotometer. Then, the transmittance (T%) was calculated using the following [Equation 1]. At this time, since the transmittance is not related to the concentration of the sample, an error in the concentration deviation according to the mixing ratio can be excluded. In addition, when the transmittance is 10, it means that 90% of the light does not pass through the sample.
* A= 450 nm 흡광도값* A= 450 nm absorbance value
또한, 침전성을 분석하기 위하여, 분말 간 응집력에 의해 발생한 침전물의 양 및 침전물 낸 공극률 증가로 높아진 침전물의 높이를 측정하였다. 상기 복합 추출물 분말 과립 각각을 마시는 물 100 ㎖가 포함된 단위면적 15.7 cm2 유리병에 10 g씩 첨가하고 섞은 다음 실온에서 7일 동안 방치한 후 상층액을 제거하였다. 그 다음, 유리병 단위면적당 침전된 침전물의 높이를 측정하고, 침전물을 70℃에서 6 시간 동안 건조한 후 침전물의 양을 측정한 다음, 하기 [수학식 2]를 이용하여 침전율(%)을 계산하였다.In addition, in order to analyze the sedimentation, the amount of sediment generated by cohesion between powders and the height of the sediment increased due to the increase in the porosity of the sediment were measured. Each of the composite extract powder granules was added to a 15.7 cm 2 glass bottle with a unit area of 100 ml of drinking water at a time of 10 g, mixed, and allowed to stand at room temperature for 7 days, and then the supernatant was removed. Then, the height of the precipitated precipitate per unit area of the glass bottle was measured, the precipitate was dried at 70° C. for 6 hours, and the amount of the precipitate was measured, and then the precipitation rate (%) was calculated using the following [Equation 2]. .
대조군으로 상기 <실시예 1>에서 제조한 상추 추출물 분말 및 황금 추출물 분말을 1 : 1의 혼합비율로 혼합한 복합 추출물 분말을 이용하였다.As a control, a composite extract powder obtained by mixing the lettuce extract powder and the golden extract powder prepared in Example 1 at a mixing ratio of 1:1 was used.
그 결과, 표 1에 나타낸 바와 같이, 코팅 공정을 거치지 않은 대조군의 경우 투광도가 9.036%, 침전율이 18.9%로 나타나 용해도가 좋지 않은 반면, 코팅 공정을 거친 복합 추출물 분말 과립의 용해도가 우수함을 확인하였다. 특히, 복합 추출물 분말과 결정과당의 혼합 비율이 1 : 1.5 내지 3일 때 용해도가 현저히 우수함을 확인하였다.
As a result, as shown in Table 1, in the case of the control group that did not undergo the coating process, the transmittance was 9.036% and the precipitation rate was 18.9%, indicating that the solubility was not good, while it was confirmed that the solubility of the composite extract powder granules after the coating process was excellent. . In particular, it was confirmed that the solubility was remarkably excellent when the mixing ratio of the complex extract powder and the crystal fructose was 1:1.5 to 3.
<< 실험예Experimental example 2> 상추 및 황금 복합 추출물 분말 과립에 대한 관능 평가 2> Sensory evaluation of lettuce and golden complex extract powder granules
본 발명의 상추 및 황금 복합 추출물 분말 과립의 향, 맛 및 종합적 기호도를 알아보기 위하여, 상기 <실험예 1>에서 용해도가 우수한 복합 추출물 분말 과립을 이용하여 관능평가를 수행하였다. In order to find out the flavor, taste and overall acceptability of the lettuce and golden composite extract powder granules of the present invention, sensory evaluation was performed using the composite extract powder granules having excellent solubility in the <Experimental Example 1>.
구체적으로, 관능평가는 향, 맛 및 전체적인 기호도 등이 충분히 훈련된 전문관능시험요원 20명에게 상기 <실험예 1>에서 상추 및 황금 복합 추출물 분말에 결정과당을 1 : 2.5의 중량% 비율로 혼합한 복합 추출물 분말 과립 10 g을 용해한 음용수 100 ㎖를 섭취하게 하고, 7점 척도법으로, 즉, 매우 좋음(7), 좋음(6), 약간 좋음(5), 보통(4), 약간 싫음(3), 싫음(2), 매우 싫음(1)으로 평가한 후, 그 평균점으로 판정하였다.Specifically, the sensory evaluation is a mixture of crystalline fructose in the lettuce and golden complex extract powder in the above <Experimental Example 1> to 20 professional sensory test personnel sufficiently trained in aroma, taste, and overall acceptability in a weight% ratio of 1: 2.5 Ingest 100 ml of drinking water obtained by dissolving 10 g of powdered granules of one complex extract, and in a 7-point scale, that is, very good (7), good (6), slightly good (5), fair (4), slightly disliked (3). ), dislike (2), very dislike (1), and then judged by the average score.
판정기준은 다음과 같다.The judgment criteria are as follows.
매우 좋음 : 7.0 점;Very Good: 7.0 points;
좋음 : 6.0 점;Good: 6.0 points;
약간 좋음 : 5.0 점;Slightly good: 5.0 points;
보통 : 4.0 점;Moderate: 4.0 points;
약간 싫음 : 3.0 점;Little dislike: 3.0 points;
싫음 : 2.0 점; 및Dislike: 2.0 points; And
매우 싫음 : 1.0 점.Very Dislike: 1.0 point.
그 결과, 하기 표 2에 나타낸 바와 같이, 본 발명의 상추 및 황금 복합 추출물 분말 과립의 쓴맛이 거의 느껴지지 않고 단맛 및 목넘김이 음용하기에 양호하며, 종합적 기호도가 우수함을 확인하였다.
As a result, as shown in Table 2 below, it was confirmed that the bitter taste of the lettuce and golden complex extract powder granules of the present invention was hardly felt, the sweetness and throat was good for drinking, and the overall preference was excellent.
<< 실험예Experimental example 3> 상추 및 황금 복합 추출물 분말 과립에 의한 수면 증진 확인 3> Confirmation of sleep enhancement by lettuce and golden compound extract powder
본 발명의 상추 및 황금 복합 추출물 분말 과립에 의한 수면 증진 효능을 확인하기 위하여, 상기 <실험예 1>에서 용해도가 우수한 복합 추출물 분말 과립을 이용하여 수면의 질을 분석하였다.In order to confirm the sleep enhancement effect by the lettuce and golden composite extract powder granules of the present invention, the quality of sleep was analyzed using composite extract powder granules having excellent solubility in the <Experimental Example 1>.
구체적으로, 피험자 40명을 대상으로 실험군 20명 및 대조군 20명으로 나누고, 실험군 20명에게 상기 <실험예 1>에서 상추 및 황금 복합 추출물 분말에 결정과당을 1 : 2.5의 중량% 비율로 혼합한 복합 추출물 분말 과립 10 g을 용해한 음용수 100 ㎖를 1일 1회 복용하게 하였다. 대조군 20명에게는 위약을 1일 1회 복용하게 하였다.Specifically, 40 subjects were divided into 20 subjects in the experimental group and 20 subjects in the control group, and 20 subjects were mixed with crystalline fructose in the lettuce and golden complex extract powder in the <Experimental Example 1> in a weight% ratio of 1: 2.5. 100 ml of drinking water obtained by dissolving 10 g of the complex extract powder granules was taken once a day. Twenty control subjects were given a placebo once a day.
그 다음, PSQI(Pittsburgh Sleep Quality Index)를 이용하여 수면의 질을 평가하였다. PSQI의 평가항목은 하기 [표 3]에 나타내었다. 이 때, 유효성은 실험군과 대조군에 대하여 독립 표본 t-test를 사용하였다(p<0.05). 실험 전 수면의 질을 평가하여 하기 [표 4]와 같이 각 그룹 간 유의미한 차이가 없음을 확인하였다.Then, the quality of sleep was evaluated using the Pittsburgh Sleep Quality Index (PSQI). The evaluation items of PSQI are shown in the following [Table 3]. In this case, the independent sample t-test was used for the experimental group and the control group (p<0.05). Before the experiment, the quality of sleep was evaluated and it was confirmed that there was no significant difference between each group as shown in [Table 4] below.
이 후, 7일간 수면의 질을 평가하였다. 설문지 작성은 1인당 2회 작성하며, 시료를 복용하기 전에 작성하고 7일간 시료를 복용한 후 동일한 설문지를 다시 작성하였다.After this, the quality of sleep for 7 days was evaluated. The questionnaire was filled out twice per person, before taking the sample, and after taking the sample for 7 days, the same questionnaire was filled out again.
각각의 항목에서 0점은 아무런 어려움 없다는 것을 나타내며, 3점은 심각한 어려움을 나타낸다. 7가지 컴포넌트(component) 점수들를 합산하여 하나의 전체적 점수를 산출하였고, 0~21의 점수 범위를 가진다. 0점은 아무런 어려움이 없다는 것을 나타내며, 21점은 전 방면에 걸쳐 심각한 어려움을 가지는 것을 나타낸다.
In each item, a score of 0 indicates no difficulty, and a score of 3 indicates serious difficulty. One overall score was calculated by summing the seven component scores, and the score ranged from 0 to 21. A score of 0 indicates no difficulty, and a score of 21 indicates serious difficulty in all areas.
그 결과, 표 5에 나타낸 바와 같이, 대조군에 비해 본 발명의 상추 및 황금 복합 추출물 분말 과립을 복용한 실험군의 수면 유도 효능이 보다 우수하며, 이를 통해 상추 및 황금 복합 추출물에 의해 수면의 질이 개선됨을 확인하였다.
As a result, as shown in Table 5, the sleep-inducing efficacy of the experimental group taking the lettuce and golden complex extract powder granules of the present invention is better than that of the control group, through which the quality of sleep is improved by the lettuce and golden complex extract. Was confirmed.
Control
1.08
1.05
3.225
0.004
Experimental group
2.26
1.87
6.112
0.000
Claims (14)
상기 복합 추출물은 물 및 에탄올의 혼합용매로 추출한 것이고,
상기 복합 추출물은 과립화된 분말 과립으로 제형화되는 것이며, 여기서 분말 과립은 상기 복합 추출물의 분말 및 당류를 1 : 1.5 내지 3의 중량비로 혼합하여 제형화되는 것인, 수면 질환 또는 수면 장애 예방 또는 치료용 약학적 조성물.
As a pharmaceutical composition for preventing or treating sleep disorders or sleep disorders containing a lettuce ( Lactuca sativa ) and golden ( Scutellaria baicalensis) complex extract as an active ingredient,
The complex extract is extracted with a mixed solvent of water and ethanol,
The composite extract is formulated into granulated powder granules, wherein the powder granules are formulated by mixing the powder and saccharides of the composite extract in a weight ratio of 1: 1.5 to 3, preventing sleep disorders or sleep disorders, or The therapeutic pharmaceutical composition.
According to claim 1, wherein the composite extract is a pharmaceutical composition for preventing or treating sleep disorders or sleep disorders, characterized in that the lettuce and gold are blended in a weight ratio of 1: 0.5 to 2.
1) 상추 추출물 분말 및 황금 추출물 분말을 혼합하여 복합 추출물 분말을 제조하는 단계;
2) 단계 1)의 복합 추출물 분말 및 당류를 1 : 1.5 내지 3의 중량비로 혼합하여 시드(seed)를 제조하는 단계; 및
3) 단계 2)의 시드를 유동층 과립기의 내부에 첨가하여 유동화하고, 물을 분사하여 당류가 코팅된 복합 추출물 분말 과립을 수득하는 단계.
The pharmaceutical composition for preventing or treating sleep disorders or sleep disorders according to claim 1, wherein the powder granules are prepared through the following steps:
1) preparing a composite extract powder by mixing the lettuce extract powder and the golden extract powder;
2) preparing a seed by mixing the complex extract powder and sugars of step 1) in a weight ratio of 1: 1.5 to 3; And
3) adding the seed of step 2) to the inside of the fluidized bed granulator for fluidization, and spraying water to obtain granules of complex extract powder coated with sugars.
The pharmaceutical composition of claim 1, wherein the sleep disorder or sleep disorder is selected from the group consisting of insomnia, narcolepsy, abnormal behavior during sleep, and hypersomnia.
상기 복합 추출물은 물 및 에탄올의 혼합용매로 추출한 것이고,
상기 복합 추출물은 과립화된 분말 과립으로 제형화되는 것이며, 여기서 분말 과립은 상기 복합 추출물의 분말 및 당류를 1 : 1.5 내지 3의 중량비로 혼합하여 제형화되는 것인, 건강식품.
For preventing or improving sleep disorders or sleep disorders, containing lettuce and golden complex extract as an active ingredient; For improving sleep quality; Or as a health food for changing the circadian rhythm,
The complex extract is extracted with a mixed solvent of water and ethanol,
The composite extract is to be formulated into granulated powder granules, wherein the powder granules are formulated by mixing the powder and saccharides of the composite extract in a weight ratio of 1: 1.5 to 3, health food.
2) 단계 1)의 복합 추출물 분말 및 당류를 혼합하여 시드를 제조하는 단계; 및
3) 단계 2)의 시드를 유동층 과립기의 내부에 첨가하여 유동화하고, 물을 분사하여 당류가 코팅된 복합 추출물 분말 과립을 수득하는 단계를 포함하는, 상추 및 황금 복합 추출물 분말 과립의 제조방법으로서,
상기 단계 1)에서 추출물은 물 및 에탄올의 혼합용매로 추출한 것이고,
상기 단계 2)에서 복합 추출물 분말 및 당류를 1 : 1.5 내지 3의 중량비로 혼합하는 것인, 상추 및 황금 복합 추출물 분말 과립의 제조방법.
1) preparing a composite extract powder by mixing the lettuce extract powder and the golden extract powder;
2) preparing a seed by mixing the complex extract powder and sugars of step 1); And
3) A method for producing a lettuce and golden complex extract powder granules comprising the step of adding the seed of step 2) to the inside of a fluidized bed granulator to fluidize, and spraying water to obtain a saccharide-coated complex extract powder granules. ,
The extract in step 1) was extracted with a mixed solvent of water and ethanol,
In the step 2), the composite extract powder and the saccharide are mixed in a weight ratio of 1: 1.5 to 3, wherein the lettuce and golden composite extract powder granules are prepared.
The method of claim 9, wherein the lettuce extract powder and the golden extract powder are mixed in a weight ratio of 1: 0.5 to 2 in step 1).
The method of claim 9, wherein the saccharide in step 2) is anhydrous crystalline glucose, hydrated crystalline glucose, fructose, maltose, sucrose, oligosaccharide, dextrin, cyclodextrin, xylitol, sorbitol, erythritol, palatinose, trehalose, stevioside, Sucralose, aspartame and acepartame potassium, characterized in that selected from the group consisting of, lettuce and golden complex extract powder granules manufacturing method.
Any one of claims 9, 10 and 13 prepared by the method of claim 13, lettuce and golden complex extract powder granules.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170155122A KR102245027B1 (en) | 2017-11-20 | 2017-11-20 | Composition for improving sleep disorder containing lettuce and Scutellariae extract as an active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170155122A KR102245027B1 (en) | 2017-11-20 | 2017-11-20 | Composition for improving sleep disorder containing lettuce and Scutellariae extract as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190057782A KR20190057782A (en) | 2019-05-29 |
KR102245027B1 true KR102245027B1 (en) | 2021-04-29 |
Family
ID=66672829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170155122A KR102245027B1 (en) | 2017-11-20 | 2017-11-20 | Composition for improving sleep disorder containing lettuce and Scutellariae extract as an active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102245027B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230111578A (en) | 2022-01-18 | 2023-07-25 | 삼육대학교산학협력단 | Pharmaceutical composition and food composition for prevention or treatment or improvement sleep disorders or inflammatory disease comprising leaf extract Hemerocallis fulva, or fractions thereof, or compounds isolated from therefrom |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1334016A (en) * | 2001-08-01 | 2002-02-06 | 宋连春 | scutellaria tea and its preparing process |
KR101102013B1 (en) | 2008-11-17 | 2012-01-04 | 주식회사 한국인삼공사 | Methods for Preparing Ginseng or Red Ginseng Granules with an Excellent Solubility |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1548053A (en) * | 2003-05-23 | 2004-11-24 | 华晶基因技术有限公司 | New use of baicalin as medicine for treating anxiety neurosis |
KR20140064280A (en) * | 2012-11-20 | 2014-05-28 | 노태진 | Somniferous composition comprising the extracts, fractions or isolated compounds of lettuce and process for preparation thereof |
KR20160010159A (en) * | 2014-07-18 | 2016-01-27 | 노태진 | Grain syrup based on lettuce those flower stalk came up |
KR101820761B1 (en) * | 2016-04-29 | 2018-01-22 | 주식회사 벤스랩 | Composition for improving sleep disturbance and sleep inducing |
KR101779536B1 (en) | 2017-05-11 | 2017-09-18 | 주식회사농심 | Composition for treating sleep disorder and enhacning sleeping time containing polygonatum extract |
-
2017
- 2017-11-20 KR KR1020170155122A patent/KR102245027B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1334016A (en) * | 2001-08-01 | 2002-02-06 | 宋连春 | scutellaria tea and its preparing process |
KR101102013B1 (en) | 2008-11-17 | 2012-01-04 | 주식회사 한국인삼공사 | Methods for Preparing Ginseng or Red Ginseng Granules with an Excellent Solubility |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230111578A (en) | 2022-01-18 | 2023-07-25 | 삼육대학교산학협력단 | Pharmaceutical composition and food composition for prevention or treatment or improvement sleep disorders or inflammatory disease comprising leaf extract Hemerocallis fulva, or fractions thereof, or compounds isolated from therefrom |
Also Published As
Publication number | Publication date |
---|---|
KR20190057782A (en) | 2019-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100374108C (en) | Compositions for promoting sleep | |
KR101336411B1 (en) | Novel use of rice extract for improving, preventing or treating sleep disorders, anxiety, or depression | |
JP6345243B2 (en) | Enbu fermented food or beverage composition | |
KR20140064280A (en) | Somniferous composition comprising the extracts, fractions or isolated compounds of lettuce and process for preparation thereof | |
KR102157248B1 (en) | A composition for the prevention or treatment of sleep disorders containing Ledebouriella seseloides extract | |
KR101336502B1 (en) | Novel use of rice bran extract or rice bran powder for improving, preventing or treating sleep disorders, anxiety, or depression | |
KR102245027B1 (en) | Composition for improving sleep disorder containing lettuce and Scutellariae extract as an active ingredient | |
KR102262752B1 (en) | A composition for the prevention, improvement or treatment of sleep disorders containing Curcuma longa extract | |
KR101779536B1 (en) | Composition for treating sleep disorder and enhacning sleeping time containing polygonatum extract | |
KR101680013B1 (en) | Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient | |
KR102262763B1 (en) | A composition for the prevention, improvement or treatment of sleep disorders containing Curcuma longa complex extracts | |
KR20090045721A (en) | Compositions for improving sleep disturbance | |
KR101528557B1 (en) | A pharmaceutical composition comprising fermented Eastern prickly pear | |
JP4669077B1 (en) | Autonomic nerve regulator containing asparagus pseudo-leaf as active ingredient | |
CN111228350A (en) | Tibetan tea formula for improving sleep, formula extract and preparation method and application thereof | |
KR101720681B1 (en) | Composition for promoting sleep including hop extract | |
KR102275824B1 (en) | The anti-diabetes composition containing extract mixture and manufaturing method thereof | |
KR102501557B1 (en) | A composition for the prevention, improvement or treatment of sleep disorders or insomnia with reduced side effects of GABAA receptor agonist, containing Glehnia littoralis extract | |
KR102262759B1 (en) | A composition for reducing side effects of GABAA receptor agonist, comprising phloroglucinol as an effective ingredient | |
KR101948210B1 (en) | COMPOSITION FOR IMPROVING ALERTNESS AND DECREASED CONCENTRATION COMPRISING Alpinia galangal EXTRACT | |
KR102489829B1 (en) | Composition for sleeping induction comprising extracts of heukharang lettuce | |
KR101351883B1 (en) | Novel use of rice hull extract for improving, preventing or treating sleep disorders, anxiety, or depression | |
KR20120055159A (en) | A composition for reducing sleep induction time and prolonging sleeping time containing chrysanthemum indicum extract, and preparing method for the same | |
WO2024019171A1 (en) | Composition for improving ocular blood flow | |
KR101568044B1 (en) | Composition reducing anxiety and stress |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |